Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 2
2018 6
2019 5
2020 5
2021 4
2022 6
2023 3
2024 2
2025 7
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year

Filters applied: . Clear all
Page 1
Lactylation-related genes signature panel in hepatocellular carcinoma reveals the prognostic and therapeutic optimization.
Xiao T, Xu X, Zhao Z, Xue H, Guo S, Long X. Xiao T, et al. Mol Cell Oncol. 2026 Feb 22;13(1):2621475. doi: 10.1080/23723556.2026.2621475. eCollection 2026. Mol Cell Oncol. 2026. PMID: 41737892 Free PMC article.
Conversely, the high-LRGS group demonstrated heightened sensitivity to several antitumor agents, including AZD5153, cediranib, foretinib, and vorinostat, relative to the low-LRGS group. Our findings establish a robust LRGS model, offering a clinically actionable tool for p …
Conversely, the high-LRGS group demonstrated heightened sensitivity to several antitumor agents, including AZD5153, cediranib, foreti …
The chordoid glioma PRKCA D463H mutation is a kinase inactive, gain-of-function allele that induces early-onset chondrosarcoma in mice.
Calleja V, Henry JC, Cobbaut M, Sewell J, Rizzoti K, Houghton F, Boeing S, Anyanwu N, Varsani-Brown S, Snoeks T, Suárez-Bonnet A, Priestnall SL, McDonald NQ, Cameron AJM, Parker PJ. Calleja V, et al. Sci Signal. 2025 Nov 4;18(911):eadr0235. doi: 10.1126/scisignal.adr0235. Epub 2025 Nov 4. Sci Signal. 2025. PMID: 41187221 Free PMC article.
The penetrant D463H mutation in PRKCA, which encodes the kinase PKCalpha, is a biomarker and driver of chordoid glioma, a type of brain cancer. Here, we found that heterozygous knock-in expression of the D463H mutant in mice elicited the development of chondrosarcomas. ... …
The penetrant D463H mutation in PRKCA, which encodes the kinase PKCalpha, is a biomarker and driver of chordoid glioma, a type of brain c …
AZD5153 enhances the chemo-sensitivity of gemcitabine on pancreatic cancer cells in vitro and in vivo.
Zhu H, Shen M, Zhu Y, Wang R, Dong R, Huang Y, Zhu L, Li Y, Yan Y, Lou J, Zhang B, Lin N, Tan B. Zhu H, et al. Cancer Cell Int. 2025 Aug 26;25(1):315. doi: 10.1186/s12935-025-03952-2. Cancer Cell Int. 2025. PMID: 40859234 Free PMC article.
Therefore, the development of sensitive drugs for pancreatic cancer is essential. AZD5153 is a novel bivalent BET bromodomain inhibitor with multiple anti-tumor effects on malignancy. ...CONCLUSION: In conclusion, these results suggested that AZD5153 might be …
Therefore, the development of sensitive drugs for pancreatic cancer is essential. AZD5153 is a novel bivalent BET bromodomain …
Combination of PSMA targeting alpha-emitting radioligand [(212)Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models.
Liukaityte R, Stenberg VY, Kleinauskas A, Juzenas P, Urbanucci A, Juzeniene A. Liukaityte R, et al. Med Oncol. 2025 Jul 22;42(8):362. doi: 10.1007/s12032-025-02925-9. Med Oncol. 2025. PMID: 40694184 Free PMC article.
The alpha-emitting radioligand [(212)Pb]Pb-AB001, targeting prostate-specific membrane antigen (PSMA), is a promising therapy approach for prostate cancer. Bromodomain and extra-terminal (BET) protein inhibitors, such as AZD5153 and JQ1, disrupt oncogenic transcript …
The alpha-emitting radioligand [(212)Pb]Pb-AB001, targeting prostate-specific membrane antigen (PSMA), is a promising therapy approach for p …
Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors.
Zhang X, Yang Y, Zou H, Yang Y, Zheng X, Corey E, Zoubeidi A, Mitsiades N, Yu AM, Li Y, Chen HW. Zhang X, et al. Acta Pharm Sin B. 2025 Mar;15(3):1415-1429. doi: 10.1016/j.apsb.2025.01.007. Epub 2025 Jan 22. Acta Pharm Sin B. 2025. PMID: 40370549 Free PMC article.
Tumor lineage plasticity (LP) is an emerging hallmark of cancer progression. Through pharmacologically probing the function of epigenetic regulators in prostate cancer cells and organoids, we identified bromodomain protein BRD4 as a crucial player. ...Significantly, …
Tumor lineage plasticity (LP) is an emerging hallmark of cancer progression. Through pharmacologically probing the function of epigen …
Functional combinatorial precision medicine for predicting and optimizing soft tissue sarcoma treatments.
Chan SPY, Rashid MBMA, Lim JJ, Goh JJN, Wong WY, Hooi L, Ismail NN, Luo B, Chen BJ, Noor NFBM, Phua BXM, Villanueva A, Sam XX, Ong CJ, Chia CS, Abidin SZ, Yong MH, Kumar K, Ooi LL, Tay TKY, Woo XY, Toh TB, Yang VS, Chow EK. Chan SPY, et al. NPJ Precis Oncol. 2025 Mar 22;9(1):83. doi: 10.1038/s41698-025-00851-7. NPJ Precis Oncol. 2025. PMID: 40121334 Free PMC article.
From a panel of approved and investigational agents, QPOP identified AZD5153 (BET inhibitor) and pazopanib (multi-kinase blocker) as the most effective combination with superior efficacy compared to standard regimens. ...
From a panel of approved and investigational agents, QPOP identified AZD5153 (BET inhibitor) and pazopanib (multi-kinase blocker) as …
High-risk neuroblastoma: ATRX and TERT as prognostic markers and therapeutic targets. Review and update on the topic.
Gonzales-Céspedes G, Navarro S. Gonzales-Céspedes G, et al. Rev Esp Patol. 2025 Jan-Mar;58(1):100790. doi: 10.1016/j.patol.2024.100790. Epub 2025 Jan 9. Rev Esp Patol. 2025. PMID: 39793153 Review.
Preclinical results with BET inhibitors (OTX015 and AZD5153) and with 6-thio-2'-deoxyguanosine, targeting NB with TERT mutations, are promising. ...
Preclinical results with BET inhibitors (OTX015 and AZD5153) and with 6-thio-2'-deoxyguanosine, targeting NB with TERT mutations, are …
Lipid metabolism-related gene signature predicts prognosis and unveils novel anti-tumor drugs in specific type of diffuse large B cell lymphoma.
Wang C, Zhang R, Zhang H, Gao H, Zhu Y, Jiao L, Yi Z, Zhou M, Li X. Wang C, et al. Mol Med. 2024 Nov 13;30(1):210. doi: 10.1186/s10020-024-00988-4. Mol Med. 2024. PMID: 39538125 Free PMC article.
In vitro cell apoptosis and viability analysis were employed to verify the specific tumor inhibition effects of AZD5153. RESULTS: Nineteen survival related lipid metabolism genes TMEM176B, LAYN, RAB6B, MMP9, ATAD3B, SLC2A11, CD3E, SLIT2, SLC2A13, SLC43A3, CD6, SIRPG, NEK6, …
In vitro cell apoptosis and viability analysis were employed to verify the specific tumor inhibition effects of AZD5153. RESULTS: Nin …
CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.
Rahman R, Rahaman MH, Hanson AR, Choo N, Xie J, Townley SL, Shrestha R, Hassankhani R, Islam S, Ramm S, Simpson KJ, Risbridger GP, Best G, Centenera MM, Balk SP, Kichenadasse G, Taylor RA, Butler LM, Tilley WD, Conn SJ, Lawrence MG, Wang S, Selth LA. Rahman R, et al. Br J Cancer. 2024 Oct;131(6):1092-1105. doi: 10.1038/s41416-024-02810-8. Epub 2024 Aug 8. Br J Cancer. 2024. PMID: 39117800 Free PMC article.
BACKGROUND: Cyclin-dependent kinase 9 (CDK9) stimulates oncogenic transcriptional pathways in cancer and CDK9 inhibitors have emerged as promising therapeutic candidates. METHODS: The activity of an orally bioavailable CDK9 inhibitor, CDKI-73, was evaluated in prostate …
BACKGROUND: Cyclin-dependent kinase 9 (CDK9) stimulates oncogenic transcriptional pathways in cancer and CDK9 inhibitors have emerged …
39 results